View Older Stories View More Recent Stories
-
Hims & Hers expands platform to include Eli Lilly weight loss medications
-
Morgan Stanley Comments Eli Lilly (LLY) and Medicare GLP-1 Obesity Coverage
-
Amazon One Medical launches weight management program with GLP-1 drugs
-
Hims & Hers Extends Drop To 6% After Amazon Glp-1 News
-
FDA encourages testosterone therapy makers to seek low libido indication
-
Leerink Partners on Hims and Hers (HIMS): FDA meeting to discuss peptide restrictions 'clear positive,' could fill growth hole
-
Hims and Hers (HIMS) PT Raised to $25 at BofA Securities
-
Hims & Hers Health, Inc. (HIMS) Strength Tied to RFK Jr Comments on Peptides
-
Hims and Hers (HIMS) PT Lowered to $21 at BofA Securities
-
Wolfe: 'We're observing some reports of GLP-1 users refreshing their wardrobes as weight loss progresses'
-
Hims and Hers (HIMS) PT Lowered to $23 at TD Cowen
-
Canaccord on Hims and Hers (HIMS): 'Novo partnership goes live; near-term headwind to revenue, long-term tailwind to the story'
-
BofA on Hims and Hers (HIMS): '$149/month subscription fee is slightly higher than we initially expected'
-
HIMS partners with Novo Nordisk to offer FDA-approved GLP-1 medications
-
HIMS to offer Wegovy and Ozempic through partnership with Novo Nordisk
-
Street Calls of the Week
-
Hims shares set for best week on record after new Novo Nordisk deal
-
Hims & Hers hires ex-Eli Lilly PR chief Beiser as top communications officer
-
BofA Securities Upgrades Hims and Hers (HIMS) to Neutral
-
Canaccord Reiterates Buy Rating on Hims and Hers (HIMS)
-
Citi Upgrades Hims and Hers (HIMS) to Neutral
-
Hims & Hers Health, Inc. (HIMS) call put ratio 2.2 calls to 1 put as share price up 41%
-
TD Cowen: 'Wegovy Injection may be declining'
-
Needham Upgrades Hims and Hers (HIMS) to Buy
-
Nephron Upgrades Hims and Hers (HIMS) to Buy
-
BTIG Reiterates Neutral Rating on Hims and Hers (HIMS) following Novo partnership
-
Truist Reiterates Hold Rating on Hims and Hers (HIMS)
-
BofA Securities Reiterates Underperform Rating on Hims and Hers (HIMS) amid Novo partnership
-
HIMS partners with Novo Nordisk, shifts US weight loss strategy
-
Hims soars 44% on report Novo Nordisk to sell weight-loss drugs on its platform
-
FDA issues 30 warning letters to telehealth firms over GLP-1 claims
-
Prior to Market Open: Endpoint News Reports 'HIMS’ pharmacy partner will reintroduce GLP-1 pill pulled from market'
-
Jefferies: 'We appreciate and agree with what HIMS mgmt is doing'
-
Hims and Hers (HIMS) PT Lowered to $18 at Truist Securities
-
Hims and Hers (HIMS) PT Lowered to $17 at TD Cowen Amid NT Uncertainty
-
KeyBanc Reiterates Sector Weight Rating on Hims and Hers (HIMS)
-
BTIG Downgrades Hims and Hers (HIMS) to Neutral
-
Hims and Hers (HIMS) PT Lowered to $17.50 at Leerink Partners
-
Hims and Hers (HIMS) PT Lowered to $24 at Evercore ISI
-
Hims and Hers (HIMS) PT Lowered to $12.50 at BofA Securities
-
After-hours movers: Hims & Hers Health, Keysight, Bed Bath & Beyond, Myriad Genetics, and more
-
Hims & Hers Health, Inc. (HIMS) Tops Q4 EPS by 3c, Offers Guidance
-
Hims & Hers is due to report after the bell. Here's what to watch out for.
-
Hims & Hers Health Inc. set to report Q4 earnings with guidance cut fears mounting after compounded semaglutide fallout
-
Hims & Hers Health (HIMS) stock: Should you buy the dip after massive selloff?
-
Hims and Hers (HIMS) PT Lowered to $30 at Canaccord Genuity
-
Hims and Hers (HIMS) PT Lowered to $13 at BofA Securities
-
Hims and Hers (HIMS) PT Lowered to $20 at Leerink Partners
-
Needham Reiterates Hold Rating on Hims and Hers (HIMS)
-
Novo Nordisk sues Hims & Hers over compounded semaglutide products
